DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma.

Juan LiYuan LiangJian FanChunru XuBao GuanJianye ZhangBin GuoYue ShiPing WangYezhen TanQi ZhangChangwei YuanYucai WuLiqun ZhouWeimin CiXuesong Li

Published in: BMC medicine (2022)

DNA methylation subtypes pave the way for predicting patient prognosis in UC. Our results provide mechanistic rationale for evaluating SGI-110 in treating UC patients in the clinic.

Keyphrases

dna methylation
end stage renal disease
genome wide
gene expression
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
single molecule
cell free
patient reported outcomes
circulating tumor cells